Tempus announced last week that it has acquired Paige for $81.3 million, paid primarily through issuance of its common stock.

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.

The FDA’s De Novo authorization for the tool establishes a new product code category for future AI-powered digital pathology risk-stratification tools.

Researchers in the UAB Department of Pathology have developed a comprehensive breast cancer data analysis platform, MammOnc-DB, to address this issue. The platform is comprised of data from more than ...

In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade ...

Healthcare providers face significant challenges in pathology. By enabling more efficient, collaborative workflows, digital pathology solutions can help them transition from legacy analogue processes ...